Pfizer CentreSource (PCS) has commented on the impact of a recent announcement made on January 22nd regarding Pfizer's intention to divest the Feucht, Germany site and the related Heumann PCS business unit. "As a result of an extensive review of the Pfizer Global Manufacturing (PGM) Plant Network, it was determined that the capacity and capability of the Heumann PCS site are not strategic for PGM or Pfizer," said Michael J. Kosko, PCS president. "The planned sale does not impact the Fine Chemicals and Contract Manufacturing business units, which focus on steroids and drug products respectively." According to Mr. Kosko, the Heumann PCS business unit targets specialty APIs and solid dose manufacturing, and is entirely supported by manufacturing activities at the Feucht site, making the sale of the unit together with the Feucht site a logical decision.